Investment Rating - Investment rating: Buy (maintained) [1] Core Views - The company reported a stable performance in 2025, with a revenue of 4.22 billion yuan, a year-on-year decrease of 4.87%, while the net profit attributable to shareholders increased by 14.96% to 906 million yuan [3][4] - The company has implemented effective cost reduction and efficiency enhancement measures, leading to a continuous improvement in profitability [4] - The fourth quarter of 2025 saw a significant profit growth, with a net profit of 223 million yuan, up 44.81% year-on-year, despite a revenue decline of 12.09% [5] Financial Performance Summary - For 2025, the company achieved a revenue of 4.22 billion yuan, a decrease of 4.87% year-on-year, and a net profit of 906 million yuan, an increase of 14.96% [4][9] - The projected revenues for 2025, 2026, and 2027 are 4.22 billion yuan, 4.60 billion yuan, and 5.02 billion yuan, respectively, with expected year-on-year growth rates of -4.9%, 9.1%, and 9.1% [9] - The net profit for the same years is projected to be 906 million yuan, 977 million yuan, and 1.11 billion yuan, with year-on-year growth rates of 14.9%, 7.8%, and 13.6% [9] - The gross margin is expected to improve from 65.2% in 2025 to 66.2% in 2027 [12] Strategic Development - The company is focusing on a "big single product, strong category" development strategy, continuously enhancing brand building [6][7] - The company has rebranded to "China Resources Jiangzhong," further strengthening brand recognition and market influence [8]
江中药业:25年业绩平稳,盈利能力持续提升-20260130